23 completed. 23 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 23 | Completed 23 |
| Phase 3 | 3 | Completed 3 |
| Phase 1 | 2 | Completed 2 |
Follow Keratoconjunctivitis Sicca: new trials by email Literature Review of Keratoconjunctivitis Sicca trials Research Report on Keratoconjunctivitis Sicca
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease INV-102, Vehicle - Dry Eye Disease | Phase 2 | Completed | Invirsa, Inc. | 109 | 2024-03-27 | 2026-09-18 |
| Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease INV-102, Vehicle - Dry Eye Disease | Phase 1 / Phase 2 | Completed | Invirsa, Inc. | 84 | 2022-08-30 | 2026-09-18 |
| Levocarnitine for Dry Eye in Sjogren's Syndrome Levocarnitine, Placebo - Sjogren's Syndrome, Keratoconjunctivitis Sicca | Phase 2 | Completed | Vanderbilt University Medical Center | 15 | 2021-11-17 | 2025-12-04 |
| Mesenchymal Stem Cell Therapy of Dry Eye Disease in Patients With Sjögren's Syndrome ASCs, Cryostor CS10 - Keratoconjunctivitis Sicca, in Sjogren's Syndrome | Phase 2 | Completed | Copenhagen University Hospital, Rigshospitalet | 40 | 2020-11-03 | 2023-03-08 |
| A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease ECF843, ECF843 vehicle - Dry Eye | Phase 2 | Completed | Novartis Pharmaceuticals | 718 | 2020-10-06 | 2025-01-28 |
| Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome 0.05% Voclosporin Ophthalmic Solution (VOS), 0.10% VOS, 0.20% VOS - Dry Eye Syndrome, Keratoconjunctivitis Sicca | Phase 2 / Phase 3 | Completed | Aurinia Pharmaceuticals Inc. | 508 | 2019-10-14 | 2021-12-10 |
| Effects of RP101 in Post-menopausal Women With Dry Eye Syndrome RP101 - Dry Eye Syndromes | Phase 2 | Completed | Redwood Pharma AB | 104 | 2019-01-18 | 2019-12-20 |
| Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca OTX-101 0.05%, OTX-101 0.09%, Vehicle - Keratoconjunctivitis Sicca, Dry Eye Disease | Phase 2 / Phase 3 | Completed | Sun Pharmaceutical Industries Limited | 455 | 2014-09-01 | 2022-08-29 |
| Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease KPI-121, Placebo - Dry Eye Syndromes, Keratoconjunctivitis Sicca | Phase 2 | Completed | Kala Pharmaceuticals, Inc. | 150 | 2014-06-01 | 2021-01-06 |
| A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES) Low Dose 0.155µg/mL SkQ1 ophthalmic solution, High Dose 1.55µg/mL SkQ1 ophthalmic solution, Placebo (Vehicle) opthalmic solution - Keratoconjunctivitis Sicca | Phase 2 | Completed | Mitotech, SA | 91 | 2014-04-01 | 2020-11-02 |
| Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, Placebo Ophthalmic Solution - Chronic Graft-versus-host Disease | Phase 2 | Completed | Rigel Pharmaceuticals | 35 | 2014-03-01 | 2016-10-10 |
| Safety and Efficacy of PG101 for Dry Eye Syndrome PG101 - Dry Eye Syndrome | Phase 1 / Phase 2 | Completed | Rhodes Pharmaceuticals, L.P. | 72 | 2013-12-01 | 2014-03-05 |
| To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, Placebo - Keratoconjunctivitis Sicca | Phase 2 | Completed | Rigel Pharmaceuticals | 204 | 2013-07-01 | 2016-10-03 |
| Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease) Lotemax, Restasis, Soothe® Lubricant Eye Drops - Keratoconjunctivitis Sicca | Phase 2 | Completed | Bausch & Lomb Incorporated | 102 | 2013-05-17 | 2019-08-30 |
| Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea rebamipide 2% ophthalmic suspension, placebo eye drops - Keratoconjunctivitis Sicca, Dry Eye | Phase 2 | Completed | Kubota Vision Inc. | 116 | 2010-02-01 | 2012-01-11 |
| Dry Eye Assessment and Management: Feasibility Study Omega-3 EFA Supplement, Olive Oil - Dry Eye Syndromes, Keratoconjunctivitis Sicca | Phase 2 / Phase 3 | Completed | Asbell, Penny, M.D. | 23 | 2010-01-01 | 2012-08-23 |
| Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye rebamipide 2% ophthalmic suspension, placebo eye drops - Dry Eye Syndromes, Keratoconjunctivitis Sicca | Phase 2 | Completed | Kubota Vision Inc. | 220 | 2009-12-01 | 2012-01-11 |
| Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome AT01, AT02, AT03 - Dry Eye Syndromes, Keratoconjunctivitis Sicca | Phase 2 | Completed | Dhp Korea Co., Ltd. | 72 | 2008-11-01 | 2010-04-02 |
| Safety and Efficacy Study of RX-10045 on the Signs and Symptoms of Dry Eye RX-10045, Placebo - Dry Eye Syndrome | Phase 2 | Completed | Resolvyx Pharmaceuticals, Inc | 232 | 2008-11-01 | 2010-09-24 |
| Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca CF101, Placebo - Keratoconjunctivitis Sicca | Phase 2 | Completed | Can-Fite BioPharma | 80 | 2007-01-01 | 2022-05-09 |
Showing 20 of 23. Sign in to see all of them.
Dry Eye Syndromes (19) · Sjogren's Syndrome (3) · Bronchiolitis Obliterans Syndrome (1) · Fatigue (1) · Hyperemia (1) · Inflammation (1) · Keratitis (1) · Keratoconjunctivitis (1) · Pain (1) · Xerophthalmia (1) · Xerostomia (1)
Conjunctival Diseases (23) · Conjunctivitis (23) · Corneal Diseases (23) · Eye Diseases (23) · Lacrimal Apparatus Diseases (23) · Keratitis (22) · Keratoconjunctivitis (22) · Dry Eye Syndromes (4) · Immune System Diseases (4) · Mouth Diseases (4) · Salivary Gland Diseases (4) · Stomatognathic Diseases (4) · Arthritis (3) · Arthritis, Rheumatoid (3) · Autoimmune Diseases (3)
Loteprednol Etabonate (2) · rebamipide (2) · CF101 (1) · Carnitine (1) · Cyclosporine (1) · Cyclosporins (1) · Gels (1) · Health Services Needs and Demand (1) · Olive Oil (1) · Rituximab (1) · Sodium Chloride (1) · isopropyl 5,12-hydroxypentadeca-8,10-dien-6,14-diynoate (1) · pimecrolimus (1)
Invirsa, Inc. (2) · Kubota Vision Inc. (2) · Rigel Pharmaceuticals (2) · Asbell, Penny, M.D. (1) · Aurinia Pharmaceuticals Inc. (1) · Bausch & Lomb Incorporated (1) · Can-Fite BioPharma (1) · Copenhagen University Hospital, Rigshospitalet (1) · Dhp Korea Co., Ltd. (1) · Kala Pharmaceuticals, Inc. (1) · Mitotech, SA (1) · National Eye Institute (NEI) (1) · Novartis (1) · Novartis Pharmaceuticals (1) · Redwood Pharma AB (1)
United States (18) · Denmark (2) · Austria (1) · Germany (1) · Hungary (1) · Israel (1) · South Korea (1)
Gail Torkildsen, MD (2) · Robert Shalwitz, MD (2) · Anne Marie Lynge Pedersen, PhD, DDS (1) · Christine Shieh, MD (1) · Daniel Magilavy, MD (1) · David Evans, OD (1) · Gail Torkildsen, M.D. (1) · Gary Foulks, Dr. (1) · Gregg Berdy, MD (1) · Hungwon Tchah,, MD (1) · Irit Bareket, MD (1) · Jeffrey Whitsett, MD (1) · Jodi Luchs, MD (1) · Joel Geffin, MD (1) · John Lonsdale, MD (1)
PMID 20304499, PMID 26733410, PMID 32826644, PMID 33710587, PMID 36944128
R34EY017626 (1)